Market Overview

UPDATE: Morgan Stanley Reiterates On Allscripts Healthcare Solutions Following Solid Bookings Performance

Related MDRX
Cookeville Medical Center Selects Allscripts for Chronic Care Management (CCM) Program
Allscripts Partners With CoverMyMeds to Help Patients Fill Prescriptions Faster
Allscripts promotes CFO to President, extends CEO's contract (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), but removed the $21.00 price target.

In the report, Morgan Stanley noted, “1Q14 bookings of $223M were up 25.5% y/y, with -18.6% seq decline reflecting seasonality (CERN was down -17.8% seq). Growth y/y reflected strength in ambulatory, population health management (PHM), managed IT services and outsourcing. PHM accounted for 36% of bookings; ex-PHM we est. core bookings were up 4.3% y/y and down -10.2% seq. MDRX added 130 new clients in the qtr, with ambulatory and PHM (particularly Care Management) driving new wins.

"SaaS contracts were 42% of bookings, up from 25% in 1Q13 and inline with 44% in 4Q13. SaaS revenues were 15% of total revenues up from 13% in 1Q13 and 14% in 4Q13. Driven by increasing SaaS mix, recurring revenues were 78% in the qtr, up from 74% in both 1Q13 and 4Q13.”

Allscripts Healthcare Solutions closed on Thursday at $14.99.

Latest Ratings for MDRX

Sep 2015Canaccord GenuityInitiates Coverage onBuy
Aug 2015Argus ResearchUpgradesHoldBuy
Jun 2015OppenheimerInitiates Coverage onPerform

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings


Related Articles (MDRX)

Get Benzinga's Newsletters